VTYX
Ventyx Biosciences Inc
Price Chart
No historical data available
Latest Quote
$14.00
+0.00 (+0.00%)
Current Price
| Previous Close | $14.00 |
| Open | $13.99 |
| Day High | $14.00 |
| Day Low | $13.99 |
| Volume | 5,403,471 |
Stock Information
| Shares Outstanding | 71.75M |
| Total Debt | $10.02M |
| Cash Equivalents | $192.64M |
| Net Income | $-106.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.00B |
| EPS (TTM) | $-1.49 |
| Exchange | NMS |
Recent Price History
No history data available. Data will be fetched automatically.
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.
đ° Latest News
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?
Zacks âĸ 2026-03-05T13:12:00Z
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
Motley Fool âĸ 2026-02-14T16:18:41Z
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
Motley Fool âĸ 2026-02-14T16:07:32Z
Eli Lilly, BioAge chase NLRP3 inhibitors with âpipeline in a pillâ potential
Pharma Voice âĸ 2026-01-29T08:00:00Z
Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple
Simply Wall St. âĸ 2026-01-25T22:07:11Z
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Motley Fool âĸ 2026-01-20T23:17:28Z
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026?
Motley Fool âĸ 2026-01-17T19:00:00Z
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
MarketBeat âĸ 2026-01-13T22:29:00Z
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
Investor's Business Daily âĸ 2026-01-12T21:20:13Z
Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences
Insider Monkey âĸ 2026-01-10T19:57:13Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $148,450,000 | $207,994,000 | $113,136,000 | $67,147,000 |
| Other Income Expense | $-88,000 | $-42,000 | $41,000 | $-16,578,000 |
| Other Non Operating Income Expenses | $-88,000 | $-42,000 | $41,000 | $-5,527,000 |
| Net Non Operating Interest Income Expense | $13,416,000 | $15,074,000 | $4,669,000 | $-21,000 |
| Operating Expense | $148,450,000 | $207,994,000 | $113,136,000 | $67,147,000 |
| General And Administrative Expense | $31,448,000 | $32,227,000 | $25,398,000 | $8,666,000 |
| Interest Expense | - | - | $0 | $99,000 |
| Interest Expense Non Operating | - | - | $0 | $99,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 |
| Net Interest Income | $13,416,000 | $15,074,000 | $4,669,000 | $-21,000 |
| Interest Income | $13,416,000 | $15,074,000 | $4,669,000 | $78,000 |
| Normalized Income | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-72,695,000 |
| Net Income From Continuing And Discontinued Operation | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 |
| Total Operating Income As Reported | $-148,450,000 | $-207,994,000 | $-113,136,000 | $-67,147,000 |
| Net Income Common Stockholders | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-85,298,000 |
| Net Income | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 |
| Net Income Including Noncontrolling Interests | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 |
| Net Income Continuous Operations | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 |
| Pretax Income | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 |
| Interest Income Non Operating | $13,416,000 | $15,074,000 | $4,669,000 | $78,000 |
| Operating Income | $-148,450,000 | $-207,994,000 | $-113,136,000 | $-67,147,000 |
| Per Share | ||||
| Diluted EPS | $-1.97 | $-3.30 | $-2.07 | $-6.65 |
| Basic EPS | $-1.97 | $-3.30 | $-2.07 | $-6.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-147,102,000 | $-207,053,000 | $-112,666,000 | $-72,566,000 |
| Reconciled Depreciation | $1,348,000 | $941,000 | $470,000 | $30,000 |
| EBITDA (Bullshit earnings) | $-147,102,000 | $-207,053,000 | $-112,666,000 | $-83,617,000 |
| EBIT | $-148,450,000 | $-207,994,000 | $-113,136,000 | $-83,647,000 |
| Diluted Average Shares | $68,478,172 | $58,542,974 | $52,471,003 | $12,825,598 |
| Basic Average Shares | $68,478,172 | $58,542,974 | $52,471,003 | $12,825,598 |
| Diluted NI Availto Com Stockholders | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-85,298,000 |
| Research And Development | $117,002,000 | $175,767,000 | $87,738,000 | $58,481,000 |
| Selling General And Administration | $31,448,000 | $32,227,000 | $25,398,000 | $8,666,000 |
| Other Gand A | $31,448,000 | $32,227,000 | $25,398,000 | $8,666,000 |
| Total Unusual Items | - | - | - | $-11,051,000 |
| Total Unusual Items Excluding Goodwill | - | - | - | $-11,051,000 |
| Preferred Stock Dividends | - | - | - | $1,552,000 |
| Gain On Sale Of Security | - | - | - | $-11,051,000 |
Fetched: 2026-03-04
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $254,045,000 | $243,923,000 | $353,895,000 | $279,199,000 |
| Total Assets | $276,563,000 | $277,693,000 | $371,400,000 | $291,482,000 |
| Total Non Current Assets | $46,938,000 | $13,348,000 | $40,712,000 | $28,462,000 |
| Other Non Current Assets | $1,034,000 | $1,077,000 | $96,000 | $60,000 |
| Investmentin Financial Assets | $35,621,000 | $0 | $38,672,000 | $28,148,000 |
| Current Assets | $229,625,000 | $264,345,000 | $330,688,000 | $263,020,000 |
| Other Current Assets | $12,303,000 | $12,125,000 | $12,747,000 | $4,444,000 |
| Cash Cash Equivalents And Short Term Investments | $217,322,000 | $252,220,000 | $317,941,000 | $258,576,000 |
| Cash And Cash Equivalents | $27,260,000 | $51,579,000 | $64,819,000 | $70,791,000 |
| Prepaid Assets | - | - | - | $4,444,000 |
| Debt | ||||
| Total Debt | $10,794,000 | $12,506,000 | $1,558,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $9,742,000 | $11,505,000 | $1,146,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,052,000 | $1,001,000 | $412,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $22,518,000 | $33,770,000 | $17,505,000 | $12,283,000 |
| Total Non Current Liabilities Net Minority Interest | $9,742,000 | $11,505,000 | $1,146,000 | $0 |
| Current Liabilities | $12,776,000 | $22,265,000 | $16,359,000 | $12,283,000 |
| Payables And Accrued Expenses | $11,724,000 | $21,264,000 | $15,947,000 | $12,283,000 |
| Payables | $3,130,000 | $5,756,000 | $6,433,000 | $4,661,000 |
| Accounts Payable | $3,130,000 | $5,756,000 | $6,433,000 | $4,661,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $254,045,000 | $243,923,000 | $353,895,000 | $279,199,000 |
| Total Equity Gross Minority Interest | $254,045,000 | $243,923,000 | $353,895,000 | $279,199,000 |
| Stockholders Equity | $254,045,000 | $243,923,000 | $353,895,000 | $279,199,000 |
| Gains Losses Not Affecting Retained Earnings | $157,000 | $-50,000 | $-1,123,000 | $-58,000 |
| Other Equity Adjustments | $157,000 | $-50,000 | $-1,123,000 | $-58,000 |
| Retained Earnings | $-554,309,000 | $-419,187,000 | $-226,225,000 | $-117,799,000 |
| Other | ||||
| Ordinary Shares Number | $71,130,054 | $59,239,113 | $56,980,845 | $50,408,830 |
| Share Issued | $71,130,054 | $59,239,113 | $56,980,845 | $50,408,830 |
| Tangible Book Value | $254,045,000 | $243,923,000 | $353,895,000 | $279,199,000 |
| Invested Capital | $254,045,000 | $243,923,000 | $353,895,000 | $279,199,000 |
| Working Capital | $216,849,000 | $242,080,000 | $314,329,000 | $250,737,000 |
| Capital Lease Obligations | $10,794,000 | $12,506,000 | $1,558,000 | $0 |
| Total Capitalization | $254,045,000 | $243,923,000 | $353,895,000 | $279,199,000 |
| Additional Paid In Capital | $808,190,000 | $663,154,000 | $581,237,000 | $397,051,000 |
| Capital Stock | $7,000 | $6,000 | $6,000 | $5,000 |
| Common Stock | $7,000 | $6,000 | $6,000 | $5,000 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $9,742,000 | $11,505,000 | $1,146,000 | $0 |
| Current Capital Lease Obligation | $1,052,000 | $1,001,000 | $412,000 | $0 |
| Current Accrued Expenses | $8,594,000 | $15,508,000 | $9,514,000 | $7,622,000 |
| Investments And Advances | $35,621,000 | $0 | $38,672,000 | $28,148,000 |
| Available For Sale Securities | $35,621,000 | - | $38,672,000 | $28,148,000 |
| Net PPE | $10,283,000 | $12,271,000 | $1,944,000 | $254,000 |
| Accumulated Depreciation | $-470,000 | $-259,000 | $-95,000 | $-24,000 |
| Gross PPE | $10,753,000 | $12,530,000 | $2,039,000 | $278,000 |
| Leases | $283,000 | $0 | - | - |
| Construction In Progress | $15,000 | $157,000 | $0 | - |
| Other Properties | $9,814,000 | $11,687,000 | $1,679,000 | $134,000 |
| Machinery Furniture Equipment | $641,000 | $686,000 | $360,000 | $144,000 |
| Properties | $0 | $0 | - | - |
| Other Short Term Investments | $190,062,000 | $200,641,000 | $253,122,000 | $187,785,000 |
| Other Investments | - | - | - | $28,148,000 |
Fetched: 2026-03-04
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-131,114,000 | $-167,036,000 | $-99,046,000 | $-38,912,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-130,873,000 | $-166,522,000 | $-98,771,000 | $-38,650,000 |
| Cash Flow From Continuing Operating Activities | $-130,873,000 | $-166,522,000 | $-98,771,000 | $-38,650,000 |
| Operating Gains Losses | $136,000 | - | - | $11,051,000 |
| Investing Activities | ||||
| Capital Expenditure | $-241,000 | $-514,000 | $-275,000 | $-262,000 |
| Investing Cash Flow | $-15,506,000 | $100,940,000 | $-74,931,000 | $-214,365,000 |
| Cash Flow From Continuing Investing Activities | $-15,506,000 | $100,940,000 | $-74,931,000 | $-214,365,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $121,649,000 | $48,408,000 | $165,398,000 | $323,036,000 |
| Financing Cash Flow | $122,115,000 | $53,329,000 | $167,772,000 | $323,551,000 |
| Cash Flow From Continuing Financing Activities | $122,115,000 | $53,329,000 | $167,772,000 | $323,551,000 |
| Net Preferred Stock Issuance | $26,603,000 | $0 | $0 | $164,221,000 |
| Preferred Stock Issuance | $26,603,000 | $0 | $0 | $164,221,000 |
| Net Common Stock Issuance | $95,046,000 | $48,408,000 | $165,398,000 | $158,815,000 |
| Common Stock Issuance | $95,046,000 | $48,408,000 | $165,398,000 | $158,815,000 |
| Other | ||||
| End Cash Position | $28,235,000 | $52,554,000 | $64,819,000 | $70,791,000 |
| Beginning Cash Position | $52,554,000 | $64,819,000 | $70,791,000 | $244,000 |
| Effect Of Exchange Rate Changes | $-55,000 | $-12,000 | $-42,000 | $11,000 |
| Changes In Cash | $-24,264,000 | $-12,253,000 | $-5,930,000 | $70,536,000 |
| Proceeds From Stock Option Exercised | $466,000 | $4,921,000 | $2,374,000 | $65,000 |
| Net Investment Purchase And Sale | $-15,265,000 | $101,454,000 | $-74,656,000 | $-216,002,000 |
| Sale Of Investment | $268,385,000 | $373,725,000 | $272,580,000 | $16,500,000 |
| Purchase Of Investment | $-283,650,000 | $-272,271,000 | $-347,236,000 | $-232,502,000 |
| Net PPE Purchase And Sale | $-241,000 | $-514,000 | $-275,000 | $-262,000 |
| Purchase Of PPE | $-241,000 | $-514,000 | $-275,000 | $-262,000 |
| Change In Working Capital | $-10,563,000 | $5,806,000 | $-5,157,000 | $4,016,000 |
| Change In Other Current Liabilities | $-847,000 | $-59,000 | $-326,000 | $0 |
| Change In Payables And Accrued Expense | $-9,557,000 | $5,249,000 | $3,505,000 | $8,402,000 |
| Change In Accrued Expense | $-6,913,000 | $5,994,000 | $1,892,000 | $5,959,000 |
| Change In Payable | $-2,644,000 | $-745,000 | $1,613,000 | $2,443,000 |
| Change In Account Payable | $-2,644,000 | $-745,000 | $1,613,000 | $2,443,000 |
| Change In Prepaid Assets | $-159,000 | $616,000 | $-8,336,000 | $-4,386,000 |
| Other Non Cash Items | $-88,000 | - | - | $27,269,000 |
| Stock Based Compensation | $22,931,000 | $28,588,000 | $16,570,000 | $2,730,000 |
| Asset Impairment Charge | $0 | $285,000 | $0 | - |
| Amortization Of Securities | $-9,515,000 | $-9,180,000 | $-2,228,000 | $0 |
| Depreciation Amortization Depletion | $1,348,000 | $941,000 | $470,000 | $30,000 |
| Depreciation And Amortization | $1,348,000 | $941,000 | $470,000 | $30,000 |
| Depreciation | $1,348,000 | $941,000 | $470,000 | $30,000 |
| Gain Loss On Sale Of PPE | $136,000 | $0 | - | - |
| Net Income From Continuing Operations | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 |
| Issuance Of Debt | - | - | $0 | $450,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $450,000 |
| Net Long Term Debt Issuance | - | - | $0 | $450,000 |
| Long Term Debt Issuance | - | - | $0 | $450,000 |
| Net Business Purchase And Sale | - | - | $0 | $1,899,000 |
| Sale Of Business | - | - | $0 | $1,899,000 |
| Income Tax Paid Supplemental Data | - | - | - | $3,000 |
| Gain Loss On Investment Securities | - | - | - | $11,051,000 |
Fetched: 2026-03-04